AVTX
Avalo Therapeutics
$19.50
+$1.06 (+5.75%)Jul 27, 2026
Key metrics
The numbers that frame AVTX today
- Market cap
- $1.03B
- P/E (TTM)
- -12.1
- EV / FCF
- -16.8
- Gross margin
- 100%
- EV / Sales
- 16,947.4
- ROIC
- -123.5%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $6.21
- 52wk High
- $24.27
Growth
Revenue and earnings trend for AVTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about AVTX
Is Avalo Therapeutics a good buy?
Hold. Avalo Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Avalo Therapeutics is selling at a very high price.
What is the market capitalization of AVTX?
Avalo Therapeutics's market capitalization is $1.03B.
What is the P/E ratio for AVTX stock?
Avalo Therapeutics's current P/E ratio is -12.1.
What is the 52-week high for AVTX stock?
The 52-week high for Avalo Therapeutics is $24.27. The current close of $19.50 is 19.7% below that high.
What is the 52-week low for AVTX stock?
The 52-week low for Avalo Therapeutics is $6.21. The current close of $19.50 is 214% above that low.
Does AVTX stock pay dividends?
Avalo Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for AVTX?
Avalo Therapeutics's Debt / Equity ratio is 0.